There has been heightened activity in
Takeda Pharmaceutical Co. recently with a call for value investors to consider the stock. The company has been highlighted as one of the best pharmaceutical stocks for income investment. Despite a fall in their
operating profit and stocks slipping, Takeda shareholders have seen a
8.8% CAGR over last three years. They have unveiled an
employee incentive plan and made strides in sustainable pharma innovation. Takeda and
Sun Pharma have introduced the
Vonoprazan drug in India and signed licensing deals with Torrent Pharmaceuticals and ImmunoGen. However, concerns persist amid the stock slipping and taking on risk through debt, leading to a gap down in share price. The stock has also been affected by a decreasing yen, though the equity has potential for long-term investors.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Wed, 21 Aug 2024 18:20:47 GMT -
Rating 2
- Innovation -1
- Information 6
- Rumor 5
